Vanguard Group Inc Kymera Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
A detailed history of Vanguard Group Inc transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 4,822,416 shares of KYMR stock, worth $239 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,822,416
Previous 4,767,050
1.16%
Holding current value
$239 Million
Previous $192 Million
24.88%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding KYMR
# of Institutions
165Shares Held
63.1MCall Options Held
22.6KPut Options Held
14.4K-
Price T Rowe Associates Inc Baltimore, MD6.39MShares$316 Million0.02% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$297 Million2.38% of portfolio
-
Atlas Venture Life Science Advisors, LLC5.35MShares$265 Million21.28% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$255 Million4.71% of portfolio
-
Wellington Management Group LLP Boston, MA4.31MShares$213 Million0.02% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.71B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...